Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis

Abstract

The invention relates to an oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis, which is prepared by adopting the following raw materials of traditional Chinese medicines in parts by weight: 15+ / -3 of roasted astragalus root, 10+ / -2 of American ginseng, 10+ / -2 of white atractylodes rhizome, 10+ / -2 of tall gastrodia tuber, 10+ / -2 of medlar, 10+ / -2 of prepared rehmannia root, 10+ / -2 of white peony root, 10+ / -2 of radix salviae miltiorrhizae, 10+ / -2 of angelica, 10+ / -2 of rhizoma ligustici wallichii, 10+ / -2 of herba epimedii, 15+ / -3 of spine date seed, 10+ / -2 of tuckahoe, 10+ / -2 of rhizoma anemarrhenae, 10+ / -2 of rhizoma cyperi, 10+ / -2 of radix bupleuri, 10+ / -2 of TurmericRoot-tuber and 6+ / -1.2 of roasted licorice. The observation of clinical curative effect proves that the total effective rate of the invention for treating the anxiety neurosis is 92.2%; the total effective rate of the invention for treating the melancholia is 91.0%. The curative effect of the oral traditional Chinese medicine preparation is similar to the curative effect of the western medicines of buspirone for treating the anxiety neurosis and fluoxetine for treating the melancholia. Moreover, the traditional Chinese medicine preparation has no obvious toxic or side effect and can be taken for a long time. The preparation has small dose, easy release of the effective components of the medicine, quick absorption, full exertion of the medicine effect, convenient carrying and easy taking and is beneficial to large-scale production.

Description

technical field [0001] The invention belongs to medical preparations, in particular an oral Chinese medicine preparation for treating depression and anxiety made from natural raw materials. Background technique [0002] Depression and anxiety are major diseases that endanger human mental health. With the accelerated pace of modern life, depression and anxiety are spreading, the age of onset is decreasing year by year, and the population of onset is expanding year by year. Depression will become the second most common disease after cardiovascular disease by 2020. Recently, according to statistics, the incidence of various types of depression in my country has reached 26 million, of which teenagers account for a large proportion. Therefore, the development of antidepressant drugs has important economic and social benefits. [0003] Depression and anxiety are like twin brothers, often co-morbid, sometimes difficult to distinguish. The National Comorbidity Survey in the United...

AI Technical Summary

Problems solved by technology

[0004] Currently, antidepressant and anxiolytic drugs mainly include tricyclics, benzodiazepines, and Although chemical drugs such as serotonin reuptake inhibitors and monoamine oxidase inhibitors have certain therapeutic effects on various degrees of depression and anxiety, they also have the disadvantages of relatively large toxic and side effects, which affect the treatment to a certain extent. long-term application

Images